Cross-Sector entity
All 1 tracked stories fall under one category: clinical-trial. Dr. Marc Siegel is most often covered alongside Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal), which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Dr. Marc Siegel, all published on August 18, 2026.
1 verified story tracked
Last mentioned: 6d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Dr. Marc Siegel is most often covered alongside Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal), which appears in 1 of these 1 story. We currently track 1 Cross-Sector story that mention Dr. Marc Siegel, all published on August 18, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Marc Siegel. Shared-story counts are live from our verified record — not editorial picks.
Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.
Source: fox7austin.com · fox32chicago.com
